Epigenetics and cancer metabolism

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 309-314

  Johnson, Christelle ^a,b   Warmoes, Marc O ^c,d   Shen, Xiling ^a   Locasale, Jason W ^b  

^a Cornell University   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amino acid metabolism; Cancer; Epigenetics; Glucose flux; Metabolism

Indexed keywords

3,3' DIINDOLYLMETHANE; ALLYLMERCAPTAN; ANACARDIC ACID; ANTINEOPLASTIC AGENT; ASPARAGINE; BETAINE; BETULIN; BUTYRIC ACID; CAMBINOL; CHOLINE; CURCUMIN; DEOXYGLUCOSE; DNA; EPIGALLOCATECHIN GALLATE; FLAVONOID; FLUOROURACIL; FOLIC ACID; GARCINOL; GENISTEIN; HISTONE; HYDROXYCITRIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANNOHEPTULOSE; METHIONINE; METHOTREXATE; NATURAL PRODUCT; SHORT HAIRPIN RNA; SULFORAPHANE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN B GROUP; GLUCOSE;

ADAPTATION; AMINO ACID METABOLISM; CANCER GENETICS; CANCER METABOLISM; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; COENZYME; DRUG DEVELOPMENT; ENZYME SUBSTRATE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; METABOLISM; METABOLITE; NONHUMAN; NUTRIENT; ONCOGENE; PROTEIN PROCESSING; SHORT SURVEY; TUMOR MICROENVIRONMENT; CITRIC ACID CYCLE; DNA METHYLATION; ENERGY METABOLISM; GENETIC EPIGENESIS; GENETICS; GLYCOLYSIS; NEOPLASMS; PHYSIOLOGY;

CELL PROLIFERATION; CITRIC ACID CYCLE; DNA METHYLATION; ENERGY METABOLISM; EPIGENESIS, GENETIC; GLUCOSE; GLYCOLYSIS; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR MICROENVIRONMENT;

EID: 84920133820     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.043     Document Type: Review

References (88)

1. Van Speybroeck L. From epigenesis to epigenetics. Annals of the New York Academy of Sciences 2002, 981:61-81.
2. Barker D.J.P., Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. The Lancet 1986, 327:1077-1081.
3. Pembrey M.E., Bygren L.O., Kaati G., Edvinsson S., Northstone K., Sjostrom M., Golding J. Sex-specific, male-line transgenerational responses in humans. European Journal Human Genetics 2005, 14:159-166.
4. Kaati G., Bygren L.O., Pembrey M., Sjostrom M. Transgenerational response to nutrition, early life circumstances and longevity. European Journal Human Genetics 2007, 15:784-790.
5. Morgan H.D., Santos F., Green K., Dean W., Reik W. Epigenetic reprogramming in mammals. Human Molecular Genetics 2005, 14:R47-R58.
6. Esteller M. Epigenetics in cancer. New England Journal of Medicine 2008, 358:1148-1159.
7. Lillycrop K.A., Burdge G.C. Epigenetic mechanisms linking early nutrition to long term health. Best Practice and Research Clinical Endocrinology and Metabolism 2012, 26:667-676.
8. Marjanovic N.D., Weinberg R.A., Chaffer C.L. Cell plasticity and heterogeneity in cancer. Clinical Chemistry 2013, 59:168-179.
9. Esteva F.J., Yu D., Hung M.-C., Hortobagyi G.N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Natural Reviews Clinical Oncology 2010, 7:98-107.
10. Collecchi P., Baldini E., Giannessi P., Naccarato A.G., Passoni A., Gardin G., Roncella M., Evangelista G., Bevilacqua G., Conte P.F. Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. European Journal of Cancer 1998, 34:1701-1704.
11. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Warburg O. On the origin of cancer cells. Science 1956.
14. Racker E. Bioenergetics and the problem of tumor growth. American Science 1972, 60:56-63.
15. Dang C. MYC, miRNA, and glutamine addiction in cancers. Cell Cycle 2009, 3243-3245.
16. Yun J., Johnson J., Hanigan C., Locasale J. Interactions between epigenetics and metabolism. Frontiers in Oncology 2012, 2.
17. Esteller M. Epigenetics provide a new generation of oncogenes and tumor-suppressor genes. British Journal of Cancer 2006, 179-183.
18. Tsukiyama T., Wu C. Chromatin remodeling and transcription. Current Opinion in Genetics and Development 1997, 7:182-191.
19. Margueron R., Reinberg D. Chromatin structure and the inheritance of epigenetic information. Natural Reviews Genetics 2010, 11:285-296.
20. Katada S., Imhof A., Sassone-Corsi P. Connecting threads: epigenetics and metabolism. Cell 2012, 148:24-28.
21. Ulrey C.L., Liu L., Andrews L.G., Tollefsbol T.O. The impact of metabolism on DNA methylation. Human Molecular Genetics 2005, 14:R139-R147.
22. Bhutani N., Burns D.M., Blau H.M. DNA demethylation dynamics. Cell 2011, 146:866-872.
23. He Y.-F., Li B.-Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., Sun Y., Li X., Dai Q., Song C.-X., Zhang K., He C., Xu G.-L. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
24. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine. Science 2011, 333:1300-1303.
25. Sandoval J., Esteller M. Cancer epigenomics: beyond genomics. Current Opinion in Genetics and Development 2012, 22:50-55.
26. Varier R.A., Timmers H.T.M. Histone lysine methylation and demethylation pathways in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on. Cancer 1815, 2011:75-89.
27. Teperino R., Schoonjans K., Auwerx J. Histone methyl-transferases and demethylases; can they link metabolism and transcription?. Cell Metabolism 2010, 12:321-327.
28. Shi Y.-J., Matson C., Lan F., Iwase S., Baba T., Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Molecular Cell 2005, 19:857-864.
29. Klose R.J., Kallin E.M., Zhang Y. JmjC-domain-containing proteins and histone demethylation. Natural Reviews Genetics 2006, 7:715-727.
30. Tsukada Y.-i., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
31. Vakoc C.R., Mandat S.A., Olenchock B.A., Blobel G.A. Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin. Molecular Cell 2005, 19:381-391.
32. Berger S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447:407-412.
33. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
34. Shahbazian M.D., Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annual Review of Biochemistry 2007, 76:75-100.
35. Racey L., Byvoet P. Histone acetyltransferase in chromatin, evidence for in vitro enzymatic transfer of acetate from acetyl-coenzyme A to histones. Experiments* Cell Research 1971, 366-370.
36. Cai L., Sutter B.M., Li B., Tu B.P. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Molecular Cell 2011, 42:426-437.
37. Imai S.-i., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
38. Finkel T., Deng C.-X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587-591.
39. Baek S.H. When signaling kinases meet histones and histone modifiers in the nucleus. Molecular Cell 2011, 42:274-284.
40. Hardie D.G. Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection. Cold Spring Harbor Symposia on Quantitative Biology 2011, 76:155-164.
41. Bungard D., Fuerth B.J., Zeng P.-Y., Faubert B., Maas N.L., Viollet B., Carling D., Thompson C.B., Jones R.G., Berger S.L. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 2010, 329:1201-1205.
42. Fujiki R., Hashiba W., Sekine H., Yokoyama A., Chikanishi T., Ito S., Imai Y., Kim J., He H.H., Igarashi K., Kanno J., Ohtake F., Kitagawa H., Roeder R.G., Brown M., Kato S. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 2011, 480:557-560.
43. Wellen K.E., Lu C., Mancuso A., Lemons J.M.S., Ryczko M., Dennis J.W., Rabinowitz J.D., Coller H.A., Thompson C.B. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes and Development 2010, 24:2784-2799.
44. Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Science 2013, 104:275-281.
45. Losman J.-A., Kaelin W.G. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes and Development 2013, 27:836-852.
46. Kaelin W.G., McKnight S.L. Influence of metabolism on epigenetics and disease. Cell 2013, 153:56-69.
47. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathology 2008, 116:597-602.
48. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 2009, 360:765-773.
49. Rakheja D., Konoplev S., Medeiros L.J., Chen W. IDH mutations in acute myeloid leukemia. Human Pathology 2012, 43:1541-1551.
50. Kerr D., Lopez H., Deshpande V., Hornicek F., Duan Z., Zhang Y., Rosenberg A., Borger D., Nielsen G. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. American Journal of Surgery Pathology 2013, 37:787-795.
51. Vandy F.C., Sisk G., Berguer R. Synchronous carotid body and thoracic paraganglioma associated with a germline SDHC mutation. Journal of Vascular Surgery 2011, 53:805-807.
52. Adam J., Yang M., Bauerschmidt C., Kitagawa M., O'Flaherty L., Maheswaran P., Ozkan G., Sahgal N., Baban D., Kato K., Saito K., Iino K., Igarashi K., Stratford M., Pugh C., Tennant D.A., Ludwig C., Davies B., Ratcliffe P.J., El-Bahrawy M., Ashrafian H., Soga T., Pollard P.J. A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia. Cell Reports 2013, 3:1440-1448.
53. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465. 966-966.
54. King A., Selak M.A., Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006, 25:4675-4682.
55. Killian J.K., Kim S.Y., Miettinen M., Smith C., Merino M., Tsokos M., Quezado M., Smith W.I., Jahromi M.S., Xekouki P., Szarek E., Walker R.L., Lasota J., Raffeld M., Klotzle B., Wang Z., Jones L., Zhu Y., Wang Y., Waterfall J.J., O'Sullivan M.J., Bibikova M., Pacak K., Stratakis C., Janeway K.A., Schiffman J.D., Fan J.-B., Helman L., Meltzer P.S. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discovery 2013, 3:648-657.
56. Letouze E., Martinelli C., Loriot C., Burnichon N., Abermil N., Ottolenghi C., Janin M., Menara M., Nguyen A.T., Benit P., Buffet A., Marcaillou C., Bertherat J., Amar L., Rustin P., De Reynies A., Gimenez-Roqueplo A.-P., Favier J. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013, 23:739-752.
57. Locasale J.W., Grassian A.R., Melman T., Lyssiotis C.A., Mattaini K.R., Bass A.J., Heffron G., Metallo C.M., Muranen T., Sharfi H., Sasaki A.T., Anastasiou D., Mullarky E., Vokes N.I., Sasaki M., Beroukhim R., Stephanopoulos G., Ligon A.H., Meyerson M., Richardson A.L., Chin L., Wagner G., Asara J.M., Brugge J.S., Cantley L.C., Vander Heiden M.G. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Natural Genetics 2011, 43:869-874.
58. Possemato R., Marks K.M., Shaul Y.D., Pacold M.E., Kim D., Birsoy K., Sethumadhavan S., Woo H.-K., Jang H.G., Jha A.K., Chen W.W., Barrett F.G., Stransky N., Tsun Z.-Y., Cowley G.S., Barretina J., Kalaany N.Y., Hsu P.P., Ottina K., Chan A.M., Yuan B., Garraway L.A., Root D.E., Mino-Kenudson M., Brachtel E.F., Driggers E.M., Sabatini D.M. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476:346-350.
59. Lu C., Thompson C.B. Metabolic regulation of epigenetics. Cell Metabolism 2012, 16:9-17.
60. Ulanovskaya O.A., Zuhl A.M., Cravatt B.F. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Natural Chemico-Biological 2013, 9:300-306.
61. Wolf A., Agnihotri S., Munoz D., Guha A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiology of Disease 2011, 44:84-91.
62. Goel A., Mathupala S.P., Pedersen P.L. Glucose metabolism in cancer: evidence that demethylation events play a role in activating type II hexokinase gene expression. Journal of Biological Chemistry 2003, 278:15333-15340.
63. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. The International Journal of Biochemistry and Cell Biology 2011, 43:969-980.
64. Lv L., Li D., Zhao D., Lin R., Chu Y., Zhang H., Zha Z., Liu Y., Li Z., Xu Y., Wang G., Huang Y., Xiong Y., Guan K.-L., Lei Q.-Y. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Molecular Cell 2011, 42:719-730.
65. Chen M., Zhang J., Li N., Qian Z., Zhu M., Li Q., Zheng J., Wang X., Shi G. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One 2011, 6:e25564. doi: 25510.21371/journal.pone.0025564, Epub 0022011 Oct 0025519.
66. Liu W., Zabirnyk O., Wang H., Shiao Y.H., Nickerson M.L., Khalil S., Anderson L.M., Perantoni A.O., Phang J.M. MiR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene 2010, 29:4914-4924.
67. Locasale J.W. The consequences of enhanced cell-autonomous glucose metabolism. Trends in Endocrinology and Metabolism 2012, 23:545-551.
68. Phang J.M., Liu W., Hancock C. Bridging epigenetics and metabolism: role of non-essential amino acids. Epigenetics 2013, 8:231-236.
69. Locasale J.W. Serine. Glycine, and one-carbon units: cancer metabolism full circle, Nature Reviews Cancer 2013, 13:572-583.
70. Landecker H. Food as exposure: nutritional epigenetics and the new metabolism. BioSocieties 2011, 6:167-194.
71. Gerhauser C. Cancer cell metabolism epigenetics and the potential influence of dietary components. A perspective. Biomedical Research 2012, 23.
72. Stefanska B., Karlic H., Varga F., Fabianowska-Majewska K., Haslberger A.G. Epigenetic mechanisms in anti-cancer actions of bioactive food components - the implications in cancer prevention. British Journal of Pharmacology 2012, 167:279-297.
73. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Natural Reviews Cancer 2009, 9:429-439.
74. Du J., Zhou Y., Su X., Yu J.J., Khan S., Jiang H., Kim J., Woo J., Kim J.H., Choi B.H., He B., Chen W., Zhang S., Cerione R.A., Auwerx J., Hao Q., Lin H. Sirt5 Is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 2011, 334:806-809.
75. Tan M., Luo H., Lee S., Jin F., Yang J.S., Montellier E., Buchou T., Cheng Z., Rousseaux S., Rajagopal N., Lu Z., Ye Z., Zhu Q., Wysocka J., Ye Y., Khochbin S., Ren B., Zhao Y. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146:1016-1028.
76. Ong T.P., Moreno F.S., Ross S.A. Targeting the epigenome with bioactive food components for cancer prevention. Journal of Nutrigenetics and Nutrigenomics 2011, 4:275-292.
77. Ross J.A., Kasum C.M. DIETARY FLAVONOIDS: bioavailability, metabolic effects, and safety. Annual Review of Nutrition 2002, 22:19-34.
78. Crozier A., Jaganath I.B., Clifford M.N. Dietary phenolics: chemistry, bioavailability and effects on health. Natural Product Reports 2009, 26:1001-1043.
79. Henikoff S., Matzke M.A. Exploring and explaining epigenetic effects. Trends in Genetics 1997, 13:293-295.
80. Gerhauser C. Cancer chemoprevention and nutri-epigenetics: state of the art and future challenges. Natural Products in Cancer Prevention and Therapy 2013, 73-132. Springer, Berlin Heidelberg. J.M. Pezzuto, N. Suh (Eds.).
81. Teicher B.A., Linehan W.M., Helman L.J. Targeting cancer metabolism. Clinical Cancer Research 2012, 18:5537-5545.
82. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
83. Robles-Fernández I., Rodríguez-Serrano F., Alvarez P., Ortiz R., Rama A., Prados J., Melguizo C., Alvarez-Manzaneda E., Aránega A. Antitumor properties of natural compounds and related molecules. Recent Pat Anticancer Drug Discov 2012, 16:16.
84. Mohanti B.K., Rath G.K., Anantha N., Kannan V., Das B.S., Chandramouli B.A.R., Banerjee A.K., Das S., Jena A., Ravichandran R., Sahi U.P., Kumar R., Kapoor N., Kalia V.K., Dwarakanath B.S., Jain V. Improving cancer radiotherapy with 2-deoxy-d-glucose: phase I/II clinical trials on human cerebral gliomas. International Journal of Radiation Oncology*Biology*Physics 1996, 35:103-111.
85. Mathupala S.P., Ko Y.H., Pedersen P.L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the warburg effect and a pivotal target for effective therapy. Seminars in Cancer Biology 2009, 19:17-24.
86. Rasschaert J., Kadiata M.M., Malaisse W.J. Effects of D-mannoheptulose upon D-glucose metabolism in tumoral pancreatic islet cells. Molecular and Cellular Biochemistry 2001, 226:77-81.
87. Alakurtti S., Makela T., Koskimies S., Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. European Journal of Pharmaceutical Sciences 2006, 29:1-13.
88. Hanai J.i., Doro N., Seth P., Sukhatme V.P. ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death Diseases 2013, 4:e696.